Abstract
Objectives/Introduction: Major Depressive Disorder is associated age-related medical conditions (e.g., diabetes mellitus type II, Alzheimer’s disease) that frequently manifest at an earlier age, contributing to excess and premature mortality. The foregoing observation provides the impetus to further refine potential mechanisms and molecular pathways subserving these disorders in order to more effectively treat these clinical populations by aiming to reduce and prevent cognitive impairment as well as downstream neurodegeneration.
Methods: A review of computerized databases was performed to identify original studies that investigated the impact of the independent and comorbid association of major depressive disorder and type II diabetes mellitus on cognitive function and conversion to Alzheimer’s disease. English-written articles were selected for review based on the adequacy of sample size, the use of standardized diagnostic instruments, and validated assessment measures.
Results: Individuals with persistent neuropsychiatric illness account for a disproportionate overall burden of disability mediated largely by decrements in cognitive performance. Mixed results from epidemiological and clinical studies suggest that insulin may mediate and/or moderate risk for cognitive dysfunction in subsets of individuals. Moreover, physiological changes, such as insulin resistance and the activation of neuroimmunoinflammatory systems result in glial and neuroendangerment.
Conclusion: Disturbances in the metabolic milieu exert a neurotoxic effect on the central nervous system and poses a hazard to other organ systems.
Keywords: Alzheimer’s disease, amyloid, dementia, depression, diabetes, GLP-1, insulin, insulin resistance, beta, tau.
CNS & Neurological Disorders - Drug Targets
Title:Major Depressive Disorder and Type II Diabetes Mellitus: Mechanisms Underlying Risk for Alzheimer’s Disease
Volume: 13 Issue: 10
Author(s): Danielle S. Cha, Andre F. Carvalho, Joshua D. Rosenblat, Muna M. Ali and Roger S. McIntyre
Affiliation:
Keywords: Alzheimer’s disease, amyloid, dementia, depression, diabetes, GLP-1, insulin, insulin resistance, beta, tau.
Abstract: Objectives/Introduction: Major Depressive Disorder is associated age-related medical conditions (e.g., diabetes mellitus type II, Alzheimer’s disease) that frequently manifest at an earlier age, contributing to excess and premature mortality. The foregoing observation provides the impetus to further refine potential mechanisms and molecular pathways subserving these disorders in order to more effectively treat these clinical populations by aiming to reduce and prevent cognitive impairment as well as downstream neurodegeneration.
Methods: A review of computerized databases was performed to identify original studies that investigated the impact of the independent and comorbid association of major depressive disorder and type II diabetes mellitus on cognitive function and conversion to Alzheimer’s disease. English-written articles were selected for review based on the adequacy of sample size, the use of standardized diagnostic instruments, and validated assessment measures.
Results: Individuals with persistent neuropsychiatric illness account for a disproportionate overall burden of disability mediated largely by decrements in cognitive performance. Mixed results from epidemiological and clinical studies suggest that insulin may mediate and/or moderate risk for cognitive dysfunction in subsets of individuals. Moreover, physiological changes, such as insulin resistance and the activation of neuroimmunoinflammatory systems result in glial and neuroendangerment.
Conclusion: Disturbances in the metabolic milieu exert a neurotoxic effect on the central nervous system and poses a hazard to other organ systems.
Export Options
About this article
Cite this article as:
Cha S. Danielle, Carvalho F. Andre, Rosenblat D. Joshua, Ali M. Muna and McIntyre S. Roger, Major Depressive Disorder and Type II Diabetes Mellitus: Mechanisms Underlying Risk for Alzheimer’s Disease, CNS & Neurological Disorders - Drug Targets 2014; 13 (10) . https://dx.doi.org/10.2174/1871527313666141130204535
DOI https://dx.doi.org/10.2174/1871527313666141130204535 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Graphene Modified Molecular Imprinting Electrochemical Sensor for Determining the Content of Dopamine
Current Analytical Chemistry Biologic Therapy in Inflammatory Eye Conditions (Ophtalmology): Safety Profile
Current Drug Safety Perspectives in Medicinal Chemistry: Focusing on the Link between Diabetes, Alzheimer's Disease and Cancer for the Discovery of New Medicines
Current Topics in Medicinal Chemistry The Role of Sodium Channels in the Mechanism of Action of Antidepressants and Mood Stabilizers
Current Drug Targets Stroke in Women - Oral Contraception, Pregnancy, and Hormone Replacement Therapy
Current Vascular Pharmacology Block Copolymers for Drug Delivery Nano Systems (DDnSs)
Current Medicinal Chemistry Tau Positive Neurons Show Marked Mitochondrial Loss and Nuclear Degradation in Alzheimer's Disease
Current Alzheimer Research Abeta Immunotherapy and Other Means to Remove Amyloid
Current Drug Targets - CNS & Neurological Disorders Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Tartaric Acid Enhances Adrenergic Receptor Activity: Test of a General Theory of Extracellular Aminergic GPCR Enhancer Discovery
Current Drug Discovery Technologies Stretch, Shrink, and Shatter the Rhythms: The Intrinsic Circadian Period in Mania and Depression
CNS & Neurological Disorders - Drug Targets Structure and Mechanism of Action of Tau Aggregation Inhibitors
Current Alzheimer Research Pharmacological Treatments for Hypochondriasis: A Review
Current Psychiatry Reviews The Immune Response to the Parasitic Nematode Trichinella and the Ways to Escape it. From Experimental Studies to Implications for Human Infection.
Current Drug Targets - Immune, Endocrine & Metabolic Disorders New Strategies in the Development of Antidepressants: Towards the Modulation of Neuroplasticity Pathways
Current Pharmaceutical Design Leptin, Immune Responses and Autoimmune Disease. Perspectives on the Use of Leptin Antagonists
Current Pharmaceutical Design Adverse Drug Reactions: Trends in a Tertiary Care Hospital
Current Drug Safety 5-HT7 Receptors
Current Drug Targets - CNS & Neurological Disorders Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Design of Multivalent Ligand Targeting G-Protein-Coupled Receptors
Current Pharmaceutical Design